NAD(+): A key metabolic regulator with great therapeutic potential for myocardial infarction via Sirtuins family

Myocardial infarction (MI) is one of the complex phenotypes of coronary artery disease, which results from the interaction of multiple genetic and environmental factors. Nicotinamide Adenine Dinucleotide (NAD(+)) is an important cofactor regulating metabolic homeostasis and a rate-limiting substrate for sirtuin (SIRT) deacetylase. Numerous NAD(+) studies have shown that it can be used as an anti-MI treatment. However, there have been few systematic reviews of the overall role of NAD(+) in treating MI. MI, which has long been a global health problem, still lacks effective treatment till now, and the discovery of NAD(+) provides a new perspective on its adjuvant treatment. This review summarizes the role of NAD(+) signaling in SIRTs in alleviating MI.